Literature DB >> 21563130

Heated, humidified air for the common cold.

Meenu Singh1, Manvi Singh.   

Abstract

BACKGROUND: Heated, humidified air has long been used by sufferers of the common cold. The theoretical basis is that steam may help congested mucus drain better and heat may destroy the cold virus as it does in vitro.
OBJECTIVES: To assess the effects of inhaling heated water vapour (steam) in the treatment of the common cold by comparing symptoms, viral shedding and nasal resistance. SEARCH STRATEGY: In this updated review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 3), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to July Week 1, 2010), EMBASE (1990 to July 2010) and Current Contents (1994 to July 2010). SELECTION CRITERIA: Randomised controlled trials (RCTs) using heated water vapour in participants with the common cold or participants with experimentally-induced common cold. DATA COLLECTION AND ANALYSIS: We reviewed all retrieved articles and excluded any articles, editorials and abstracts with inadequate outcome descriptions. The studies we included were subjected to a methodological assessment. MAIN
RESULTS: Six trials (394 trial participants) were included. Three trials in which patient data could be pooled found benefits of steam for symptom relief for the common cold (odds ratio (OR) 0.31; 95% confidence interval (CI) 0.16 to 0.60). However, results on symptom indices were equivocal. No studies demonstrated an exacerbation of clinical symptom scores. One study conducted in the USA demonstrated worsened nasal resistance, while an earlier Israeli study showed improvement. One study examined viral shedding and antibody titres in nasal washings; there was no change in either between treatment and placebo groups. Minor side effects (including discomfort or irritation of the nose) were reported in some studies. AUTHORS'
CONCLUSIONS: Steam inhalation has not shown any consistent benefits in the treatment of the common cold, hence is not recommended in the routine treatment of common cold symptoms until more double-blind, randomized trials with a standardised treatment modality are conducted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21563130     DOI: 10.1002/14651858.CD001728.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  7 in total

1.  A guide to the management of acute rhinosinusitis in primary care: management strategy based on best evidence and recent European guidelines.

Authors:  Neil Foden; Christopher Burgess; Kathryn Shepherd; Robert Almeyda
Journal:  Br J Gen Pract       Date:  2013-11       Impact factor: 5.386

2.  Treating cough and cold: Guidance for caregivers of children and youth.

Authors:  Ran D Goldman
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

Review 3.  Prevention and treatment of the common cold: making sense of the evidence.

Authors:  G Michael Allan; Bruce Arroll
Journal:  CMAJ       Date:  2014-01-27       Impact factor: 8.262

Review 4.  Heated, humidified air for the common cold.

Authors:  Meenu Singh; Manvi Singh; Nishant Jaiswal; Anil Chauhan
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

5.  Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population.

Authors:  Chongqing Tan; Sini Li; Lidan Yi; Xiaohui Zeng; Liubao Peng; Shuxia Qin; Liting Wang; Xiaomin Wan
Journal:  Adv Ther       Date:  2021-04-10       Impact factor: 3.845

6.  Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure.

Authors:  SiNi Li; JianHe Li; LiuBao Peng; YaMin Li; XiaoMin Wan
Journal:  Rheumatol Ther       Date:  2021-03-27

7.  Anakinra in pediatric acute fulminant myocarditis.

Authors:  Louise Maunier; Ramy Charbel; Virginie Lambert; Pierre Tissières
Journal:  Ann Intensive Care       Date:  2022-08-26       Impact factor: 10.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.